Sanofi Said to Weigh Actelion Bid Challenging J&J

The transcript discusses Johnson & Johnson's (J&J) potential acquisition of Actelion, highlighting the ongoing negotiations and the interest of other potential buyers. Actelion's leadership has shown resistance to selling, complicating the deal. Financial aspects, including the proposed $250 per share offer, are analyzed, with J&J's financial strength noted. The potential involvement of other pharmaceutical companies like Roche is considered, while regulatory and political factors, such as changes in U.S. administration, are also discussed.

Which companies might be interested in acquiring Actelion besides Johnson & Johnson?

How might the political climate in the US affect the timing of the acquisition deal?